By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


SEARCH JOBS

The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.


Key Statistics


Email: contactus@themedco.com
Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO
 





Collaborations

UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient

Alnylam Pharmaceuticals 





Company News
The Medicines Company (MDCO) Receives CHMP Positive Opinions For Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin) And RAPLIXA™ (sealant powder) 1/23/2015 9:10:02 AM
The Medicines Company (MDCO) Prices $350 Million Of Convertible Notes 1/8/2015 1:56:25 PM
The Medicines Company (MDCO) Announces Intention To Offer $300 Million Of Convertible Notes 1/7/2015 10:50:18 AM
The Medicines Company (MDCO) To Participate In 33rd Annual J.P. Morgan Healthcare Conference 1/6/2015 11:22:33 AM
The Medicines Company (MDCO) Reaches $55 Million Licensing Partnership With SciClone Pharmaceuticals, Inc. (SCLN) 12/18/2014 9:16:07 AM
Alnylam Pharmaceuticals (ALNY) And The Medicines Company (MDCO) Announce Initiation Of Phase 1 Clinical Trial For ALN-Pcssc, A Subcutaneously Administered Investigational Rnai Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia 12/11/2014 9:11:56 AM
The Medicines Company (MDCO) To Participate In Oppenheimer 25th Annual Healthcare Conference 12/8/2014 9:52:05 AM
The Medicines Company (MDCO) Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients 11/17/2014 11:50:11 AM
The Medicines Company (MDCO) To Present New Data On Investigational Lipid-Modifying Agent MDCO-216 And Investigational Antiplatelet Agent Cangrelor At 2014 American Heart Association Annual Scientific Sessions In Chicago 11/14/2014 9:40:57 AM
The Medicines Company (MDCO) To Participate In Credit Suisse Healthcare Conference 11/11/2014 10:39:31 AM
12345678910...
//-->